MX390653B - Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica. - Google Patents

Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.

Info

Publication number
MX390653B
MX390653B MX2018002447A MX2018002447A MX390653B MX 390653 B MX390653 B MX 390653B MX 2018002447 A MX2018002447 A MX 2018002447A MX 2018002447 A MX2018002447 A MX 2018002447A MX 390653 B MX390653 B MX 390653B
Authority
MX
Mexico
Prior art keywords
antibodies
nephritis
lupusic
treatment
therapeutic
Prior art date
Application number
MX2018002447A
Other languages
English (en)
Spanish (es)
Other versions
MX2018002447A (es
Inventor
Gerald Henry Nabozny
Juergen STEFFGEN
Meera RAMANUJAM
Paul Scholl
Scott Ronald Brodeur
Thomas B Freeman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018002447A publication Critical patent/MX2018002447A/es
Publication of MX390653B publication Critical patent/MX390653B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018002447A 2015-09-01 2016-08-31 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica. MX390653B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (2)

Publication Number Publication Date
MX2018002447A MX2018002447A (es) 2018-06-15
MX390653B true MX390653B (es) 2025-03-21

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002447A MX390653B (es) 2015-09-01 2016-08-31 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.

Country Status (16)

Country Link
US (3) US20170058038A1 (https=)
EP (1) EP3344655B1 (https=)
JP (2) JP2018529661A (https=)
KR (1) KR20180039172A (https=)
CN (1) CN107922501A (https=)
AU (1) AU2016317028B2 (https=)
BR (1) BR112018001907A2 (https=)
CA (1) CA2993996A1 (https=)
CL (1) CL2018000317A1 (https=)
DK (1) DK3344655T5 (https=)
ES (1) ES2969968T3 (https=)
HU (1) HUE063528T2 (https=)
MX (1) MX390653B (https=)
PH (1) PH12018500445B1 (https=)
PL (1) PL3344655T3 (https=)
WO (1) WO2017040566A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
US20240254248A1 (en) * 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
CN107922501A (zh) 2018-04-17
ES2969968T3 (es) 2024-05-23
US20170058038A1 (en) 2017-03-02
JP2021185169A (ja) 2021-12-09
CA2993996A1 (en) 2017-03-09
EP3344655A1 (en) 2018-07-11
EP3344655B1 (en) 2023-07-26
PH12018500445B1 (en) 2022-08-10
AU2016317028B2 (en) 2021-09-09
MX2018002447A (es) 2018-06-15
HUE063528T2 (hu) 2024-01-28
PL3344655T3 (pl) 2024-02-19
CL2018000317A1 (es) 2018-07-20
AU2016317028A1 (en) 2018-02-22
US20230265203A1 (en) 2023-08-24
DK3344655T5 (da) 2024-10-07
PH12018500445A1 (en) 2018-09-10
KR20180039172A (ko) 2018-04-17
JP2018529661A (ja) 2018-10-11
US20190177420A1 (en) 2019-06-13
BR112018001907A2 (pt) 2018-09-25
WO2017040566A1 (en) 2017-03-09
DK3344655T3 (da) 2023-10-09

Similar Documents

Publication Publication Date Title
MX390653B (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201691541A1 (ru) Новые анти-baff антитела
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2017010864A (es) Anticuerpos contra tau y sus usos.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201691521A1 (ru) Антитела к интерлейкину-21
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
MX2016014559A (es) Compuestos para el tratamiento de cancer.
PH12019502694A1 (en) Anti-trkb antibodies
DK3638293T3 (da) Sammensætninger til behandling af cancer
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201691896A1 (ru) Соединения и способы их применения
BR112018074231A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
EA201792380A1 (ru) Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен
EA201890629A1 (ru) Применение антител к cd40 для лечения волчаночного нефрита